Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

{ 'indexed': { 'date-parts': [[2023, 11, 24]], 'date-time': '2023-11-24T00:19:33Z', 'timestamp': 1700785173701}, 'reference-count': 51, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2023, 11, 23]], 'date-time': '2023-11-23T00:00:00Z', 'timestamp': 1700697600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2023, 11, 23]], 'date-time': '2023-11-23T00:00:00Z', 'timestamp': 1700697600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [{'name': 'Merck & Co, Inc.'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s40121-023-00891-1', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 11, 23]], 'date-time': '2023-11-23T06:01:41Z', 'timestamp': 1700719301000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the ' 'Randomized, Placebo-Controlled MOVe-OUT Trial', 'prefix': '10.1007', 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04575597', 'registry': '10.18810/clinical-trials-gov'}], 'author': [ { 'ORCID': 'http://orcid.org/0009-0002-3893-9374', 'authenticated-orcid': False, 'given': 'Julie M.', 'family': 'Strizki', 'sequence': 'first', 'affiliation': []}, {'given': 'Jay A.', 'family': 'Grobler', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicholas', 'family': 'Murgolo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arthur', 'family': 'Fridman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthew G.', 'family': 'Johnson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jiejun', 'family': 'Du', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patricia', 'family': 'Carmelitano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Michelle L.', 'family': 'Brown', 'sequence': 'additional', 'affiliation': []}, {'given': 'Amanda', 'family': 'Paschke', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carisa', 'family': 'De Anda', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 11, 23]]}, 'reference': [ { 'key': '891_CR1', 'unstructured': 'World Health Organization. WHO coronavirus (COVID-19) dashboard. ' 'https://covid19.who.int/. Accessed 24 Sept 2023.'}, { 'issue': '1', 'key': '891_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1614', 'DOI': '10.1038/s41467-022-29225-4', 'volume': '13', 'author': 'L Perez-Alos', 'year': '2022', 'unstructured': 'Perez-Alos L, Armenteros JJA, Madsen JR, et al. Modeling of waning ' 'immunity after SARS-CoV-2 vaccination and influencing factors. Nat ' 'Commun. 2022;13(1):1614.', 'journal-title': 'Nat Commun'}, { 'issue': '24', 'key': '891_CR3', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2114583', 'volume': '385', 'author': 'EG Levin', 'year': '2021', 'unstructured': 'Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to ' 'BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.', 'journal-title': 'N Engl J Med'}, { 'issue': '1', 'key': '891_CR4', 'doi-asserted-by': 'publisher', 'first-page': '439', 'DOI': '10.1186/s12879-022-07418-y', 'volume': '22', 'author': 'P Ssentongo', 'year': '2022', 'unstructured': 'Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine ' 'effectiveness against infection, symptomatic and severe COVID-19: a ' 'systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):439.', 'journal-title': 'BMC Infect Dis'}, { 'issue': '12', 'key': '891_CR5', 'doi-asserted-by': 'publisher', 'first-page': '2161', 'DOI': '10.1093/cid/ciac328', 'volume': '75', 'author': 'AA Butt', 'year': '2022', 'unstructured': 'Butt AA, Talisa VB, Shaikh OS, et al. Relative vaccine effectiveness of ' 'a SARS-CoV-2 mRNA vaccine booster dose against the Omicron variant. Clin ' 'Infect Dis. 2022;75(12):2161–8.', 'journal-title': 'Clin Infect Dis'}, { 'issue': '24', 'key': '891_CR6', 'doi-asserted-by': 'publisher', 'first-page': '2337', 'DOI': '10.1056/NEJMc2202879', 'volume': '386', 'author': 'PE Brown', 'year': '2022', 'unstructured': 'Brown PE, Fu SH, Bansal A, et al. Omicron BA.1/1.1 SARS-CoV-2 infection ' 'among vaccinated Canadian adults. N Engl J Med. 2022;386(24):2337–9.', 'journal-title': 'N Engl J Med'}, { 'issue': '23', 'key': '891_CR7', 'doi-asserted-by': 'publisher', 'first-page': '2201', 'DOI': '10.1056/NEJMoa2118946', 'volume': '386', 'author': 'Y Goldberg', 'year': '2022', 'unstructured': 'Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural ' 'and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201–12.', 'journal-title': 'N Engl J Med'}, { 'issue': '11', 'key': '891_CR8', 'doi-asserted-by': 'publisher', 'first-page': '2398', 'DOI': '10.1038/s41591-022-02051-3', 'volume': '28', 'author': 'B Bowe', 'year': '2022', 'unstructured': 'Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with ' 'SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398–405.', 'journal-title': 'Nat Med'}, { 'issue': '10373', 'key': '891_CR9', 'doi-asserted-by': 'publisher', 'first-page': '281', 'DOI': '10.1016/S0140-6736(22)02597-1', 'volume': '401', 'author': 'CC Butler', 'year': '2023', 'unstructured': 'Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care ' 'versus usual care alone as early treatment for adults with COVID-19 at ' 'increased risk of adverse outcomes (PANORAMIC): an open-label, ' 'platform-adaptive randomised controlled trial. Lancet. ' '2023;401(10373):281–93.', 'journal-title': 'Lancet'}, { 'issue': '8', 'key': '891_CR10', 'doi-asserted-by': 'publisher', 'first-page': 'e231', 'DOI': '10.1016/S1473-3099(22)00119-0', 'volume': '22', 'author': 'R Dal-Re', 'year': '2022', 'unstructured': 'Dal-Re R, Becker SL, Bottieau E, et al. Availability of oral antivirals ' 'against SARS-CoV-2 infection and the requirement for an ethical ' 'prescribing approach. Lancet Infect Dis. 2022;22(8):e231–8.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '8', 'key': '891_CR11', 'doi-asserted-by': 'publisher', 'first-page': 'e00766', 'DOI': '10.1128/AAC.00766-18', 'volume': '62', 'author': 'JJ Yoon', 'year': '2018', 'unstructured': 'Yoon JJ, Toots M, Lee S, et al. Orally efficacious broad-spectrum ' 'ribonucleoside analog inhibitor of influenza and respiratory syncytial ' 'viruses. Antimicrob Agents Chemother. 2018;62(8):e00766-78.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '1', 'key': '891_CR12', 'doi-asserted-by': 'publisher', 'first-page': '11', 'DOI': '10.1038/s41564-020-00835-2', 'volume': '6', 'author': 'RM Cox', 'year': '2021', 'unstructured': 'Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside ' 'analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. ' 'Nat Microbiol. 2021;6(1):11–8.', 'journal-title': 'Nat Microbiol'}, { 'issue': '541', 'key': '891_CR13', 'doi-asserted-by': 'publisher', 'first-page': 'eabb5883', 'DOI': '10.1126/scitranslmed.abb5883', 'volume': '12', 'author': 'TP Sheahan', 'year': '2020', 'unstructured': 'Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable ' 'broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial ' 'cell cultures and multiple coronaviruses in mice. Sci Transl Med. ' '2020;12(541):eabb5883.', 'journal-title': 'Sci Transl Med'}, { 'key': '891_CR14', 'doi-asserted-by': 'publisher', 'first-page': '451', 'DOI': '10.1038/s41586-021-03312-w', 'volume': '591', 'author': 'A Wahl', 'year': '2021', 'unstructured': 'Wahl A, Gralinski LE, Johnson CE, et al. SARS-CoV-2 infection is ' 'effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–7.', 'journal-title': 'Nature'}, { 'issue': '5', 'key': '891_CR15', 'doi-asserted-by': 'publisher', 'first-page': '749', 'DOI': '10.1093/infdis/jiab361', 'volume': '224', 'author': 'R Abdelnabi', 'year': '2021', 'unstructured': 'Abdelnabi R, Foo CS, De Jonghe S, et al. Molnupiravir inhibits the ' 'replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a ' 'hamster infection model. J Infect Dis. 2021;224(5):749–53.', 'journal-title': 'J Infect Dis'}, { 'key': '891_CR16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2022.105252', 'volume': '198', 'author': 'L Vangeel', 'year': '2022', 'unstructured': 'Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and ' 'nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants ' 'of concern. Antiviral Res. 2022;198: 105252.', 'journal-title': 'Antiviral Res'}, { 'issue': '7902', 'key': '891_CR17', 'doi-asserted-by': 'publisher', 'first-page': '706', 'DOI': '10.1038/s41586-022-04474-x', 'volume': '603', 'author': 'B Meng', 'year': '2022', 'unstructured': 'Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by ' 'SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature. ' '2022;603(7902):706–14.', 'journal-title': 'Nature'}, { 'issue': '10', 'key': '891_CR18', 'doi-asserted-by': 'publisher', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'volume': '386', 'author': 'E Takashita', 'year': '2022', 'unstructured': 'Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and ' 'antiviral drugs against Covid-19 Omicron variant. N Engl J Med. ' '2022;386(10):995–8.', 'journal-title': 'N Engl J Med'}, { 'issue': '7917', 'key': '891_CR19', 'doi-asserted-by': 'publisher', 'first-page': '119', 'DOI': '10.1038/s41586-022-04856-1', 'volume': '607', 'author': 'R Uraki', 'year': '2022', 'unstructured': 'Uraki R, Kiso M, Iida S, et al. Characterization and antiviral ' 'susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. ' '2022;607(7917):119–27.', 'journal-title': 'Nature'}, { 'issue': '13', 'key': '891_CR20', 'doi-asserted-by': 'publisher', 'DOI': '10.1172/jci.insight.160108', 'volume': '7', 'author': 'K Rosenke', 'year': '2022', 'unstructured': 'Rosenke K, Okumura A, Lewis MC, et al. Molnupiravir inhibits SARS-CoV-2 ' 'variants including Omicron in the hamster model. JCI Insight. ' '2022;7(13):e160108.', 'journal-title': 'JCI Insight'}, { 'issue': '24', 'key': '891_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'e01348', 'DOI': '10.1128/JVI.01348-19', 'volume': '93', 'author': 'ML Agostini', 'year': '2019', 'unstructured': 'Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-molecule antiviral ' 'beta-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus ' 'with a high genetic barrier to resistance. J Virol. ' '2019;93(24):e01348–19.', 'journal-title': 'J Virol'}, { 'issue': '3', 'key': '891_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e01965', 'DOI': '10.1128/JVI.01965-17', 'volume': '92', 'author': 'N Urakova', 'year': '2018', 'unstructured': 'Urakova N, Kuznetsova V, Crossman DK, et al. β-d-N4-Hydroxycytidine is a ' 'potent anti-alphavirus compound that induces a high level of mutations ' 'in the viral genome. J Virol. 2018;92(3):e01965–17.', 'journal-title': 'J Virol'}, { 'issue': 'Suppl 1', 'key': '891_CR23', 'doi-asserted-by': 'publisher', 'first-page': 'S373', 'DOI': '10.1093/ofid/ofab466.742', 'volume': '8', 'author': 'J Grobler', 'year': '2021', 'unstructured': 'Grobler J, Strizki J, Murgolo N, et al. Molnupiravir maintains antiviral ' 'activity against SARS-CoV-2 variants in vitro and in early clinical ' 'studies. Open Forum Infect Dis. 2021;8(Suppl 1):S373.', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '891_CR24', 'doi-asserted-by': 'publisher', 'first-page': '740', 'DOI': '10.1038/s41594-021-00651-0', 'volume': '28', 'author': 'F Kabinger', 'year': '2021', 'unstructured': 'Kabinger F, Stiller C, Schmitzova J, et al. Mechanism of ' 'molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. ' '2021;28:740–6.', 'journal-title': 'Nat Struct Mol Biol'}, { 'issue': '1', 'key': '891_CR25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jbc.2021.100770', 'volume': '297', 'author': 'CJ Gordon', 'year': '2021', 'unstructured': 'Gordon CJ, Tchesnokov EP, Schinazi RF, et al. Molnupiravir promotes ' 'SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. ' '2021;297(1):100770.', 'journal-title': 'J Biol Chem'}, { 'issue': '9', 'key': '891_CR26', 'doi-asserted-by': 'publisher', 'first-page': '706', 'DOI': '10.1038/s41594-021-00657-8', 'volume': '28', 'author': 'B Malone', 'year': '2021', 'unstructured': 'Malone B, Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct ' 'Mol Biol. 2021;28(9):706–8.', 'journal-title': 'Nat Struct Mol Biol'}, { 'issue': '6', 'key': '891_CR27', 'doi-asserted-by': 'publisher', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'volume': '386', 'author': 'A Jayk Bernal', 'year': '2022', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for ' 'oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. ' '2022;386(6):509–20.', 'journal-title': 'N Engl J Med'}, { 'issue': '8', 'key': '891_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1126', 'DOI': '10.7326/M22-0729', 'volume': '175', 'author': 'MG Johnson', 'year': '2022', 'unstructured': 'Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on ' 'biomarkers, respiratory interventions, and medical services in COVID-19: ' 'a randomized, placebo-controlled trial. Ann Intern Med. ' '2022;175(8):1126–34.', 'journal-title': 'Ann Intern Med'}, { 'key': '891_CR29', 'doi-asserted-by': 'publisher', 'author': 'Y Caraco', 'year': '2022', 'unstructured': 'Caraco Y, Crofoot GE, Moncada PA, et al. Phase\xa02/3 trial of ' 'molnupiravir for treatment of COVID-19 in nonhospitalized adults. NEJM ' 'Evid. 2022. https://doi.org/10.1056/EVIDoa2100043.', 'journal-title': 'NEJM Evid', 'DOI': '10.1056/EVIDoa2100043'}, { 'issue': '1', 'key': '891_CR30', 'doi-asserted-by': 'publisher', 'first-page': '71', 'DOI': '10.1186/s12985-021-01542-y', 'volume': '18', 'author': 'ST Sonnleitner', 'year': '2021', 'unstructured': 'Sonnleitner ST, Dorighi J, Jansen B, et al. An in vitro model for ' 'assessment of SARS-CoV-2 infectivity by defining the correlation between ' 'virus isolation and quantitative PCR value: isolation success of ' 'SARS-CoV-2 from oropharyngeal swabs correlates negatively with Cq value. ' 'Virol J. 2021;18(1):71.', 'journal-title': 'Virol J'}, { 'key': '891_CR31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jcv.2021.104879', 'volume': '141', 'author': 'AK Singh', 'year': '2021', 'unstructured': 'Singh AK, Stellrecht KA, Arunachalam T, et al. Lack of active SARS-CoV-2 ' 'virus in a subset of PCR-positive COVID-19 congregate care patients. J ' 'Clin Virol. 2021;141:104879.', 'journal-title': 'J Clin Virol'}, { 'key': '891_CR32', 'doi-asserted-by': 'publisher', 'author': 'TC Jones', 'year': '2021', 'unstructured': 'Jones TC, Biele G, Muhlemann B, et al. Estimating infectiousness ' 'throughout SARS-CoV-2 infection course. Science. 2021. ' 'https://doi.org/10.1126/science.abi5273.', 'journal-title': 'Science', 'DOI': '10.1126/science.abi5273'}, { 'issue': '7809', 'key': '891_CR33', 'doi-asserted-by': 'publisher', 'first-page': '465', 'DOI': '10.1038/s41586-020-2196-x', 'volume': '581', 'author': 'R Wölfel', 'year': '2020', 'unstructured': 'Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of ' 'hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–9.', 'journal-title': 'Nature'}, { 'issue': '67', 'key': '891_CR34', 'doi-asserted-by': 'publisher', 'first-page': '3773', 'DOI': '10.21105/joss.03773', 'volume': '6', 'author': 'I Aksamentov', 'year': '2021', 'unstructured': 'Aksamentov I, Roemer C, Hodcroft EB, et al. Nextclade: clade assignment, ' 'mutation calling and quality control for viral genomes. J Open Source ' 'Softw. 2021;6(67):3773.', 'journal-title': 'J Open Source Softw'}, { 'issue': '2', 'key': '891_CR35', 'doi-asserted-by': 'publisher', 'first-page': '183', 'DOI': '10.1016/S1473-3099(22)00644-2', 'volume': '23', 'author': 'SH Khoo', 'year': '2023', 'unstructured': 'Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in ' 'unvaccinated and vaccinated patients with early SARS-CoV-2 infection in ' 'the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, ' 'phase\xa02 trial. Lancet Infect Dis. 2023;23(2):183–95.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '1', 'key': '891_CR36', 'doi-asserted-by': 'publisher', 'first-page': '7284', 'DOI': '10.1038/s41467-022-34839-9', 'volume': '13', 'author': 'I Donovan-Banfield', 'year': '2022', 'unstructured': 'Donovan-Banfield I, Penrice-Randal R, Goldswain H, et al. ' 'Characterisation of SARS-CoV-2 genomic variation in response to ' 'molnupiravir treatment in the AGILE phase IIa clinical trial. Nat ' 'Commun. 2022;13(1):7284.', 'journal-title': 'Nat Commun'}, { 'issue': '628', 'key': '891_CR37', 'doi-asserted-by': 'publisher', 'first-page': 'eab17430', 'DOI': '10.1126/scitranslmed.abl7430', 'volume': '14', 'author': 'WA Fischer 2nd', 'year': '2022', 'unstructured': 'Fischer WA 2nd, Eron JJ Jr, Holman W, et al. A phase\xa02a clinical ' 'trial of molnupiravir in patients with COVID-19 shows accelerated ' 'SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl ' 'Med. 2022;14(628):eab17430.', 'journal-title': 'Sci Transl Med'}, { 'issue': '6', 'key': '891_CR38', 'doi-asserted-by': 'publisher', 'first-page': '1337', 'DOI': '10.1002/cpt.2895', 'volume': '113', 'author': 'A Chawla', 'year': '2023', 'unstructured': 'Chawla A, Birger R, Wan H, et al. Factors influencing COVID-19 risk: ' 'insights from molnupiravir exposure-response modeling of clinical ' 'outcomes. Clin Pharmacol Ther. 2023;113(6):1337–45.', 'journal-title': 'Clin Pharmacol Ther'}, { 'issue': '22', 'key': '891_CR39', 'doi-asserted-by': 'publisher', 'first-page': '2249', 'DOI': '10.1001/jama.2020.8259', 'volume': '323', 'author': 'N Sethuraman', 'year': '2020', 'unstructured': 'Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for ' 'SARS-CoV-2. JAMA. 2020;323(22):2249–51.', 'journal-title': 'JAMA'}, { 'issue': '1', 'key': '891_CR40', 'doi-asserted-by': 'publisher', 'first-page': 'e13', 'DOI': '10.1016/S2666-5247(20)30172-5', 'volume': '2', 'author': 'M Cevik', 'year': '2021', 'unstructured': 'Cevik M, Tate M, Llloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV ' 'viral load dynamics, duration of viral shedding, and infectiousness: a ' 'systematic review and meta-analysis. Lancet Microbe. 2021;2(1):e13–22.', 'journal-title': 'Lancet Microbe'}, { 'issue': '3', 'key': '891_CR41', 'first-page': '147', 'volume': '21', 'author': 'O Puhach', 'year': '2023', 'unstructured': 'Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding ' 'kinetics. Nat Rev Microbiol. 2023;21(3):147–61.', 'journal-title': 'Nat Rev Microbiol'}, { 'issue': '17', 'key': '891_CR42', 'doi-asserted-by': 'publisher', 'first-page': '2769', 'DOI': '10.1016/j.vaccine.2023.03.044', 'volume': '41', 'author': 'S-W Kang', 'year': '2023', 'unstructured': 'Kang S-W, Park H, Kim JY, et al. Comparison of culture-competent virus ' 'shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination ' 'status: a prospective cohort study. Vaccine. 2023;41(17):2769–72.', 'journal-title': 'Vaccine'}, { 'issue': '3', 'key': '891_CR43', 'doi-asserted-by': 'publisher', 'first-page': '275', 'DOI': '10.1056/NEJMc2202092', 'volume': '387', 'author': 'J Boucau', 'year': '2022', 'unstructured': 'Boucau J, Marino C, Regan J, et al. Duration of shedding of culturable ' 'virus in SARS-CoV-2 Omicron (BA.1) infection. N Engl J Med. ' '2022;387(3):275–7.', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '891_CR44', 'doi-asserted-by': 'publisher', 'first-page': '468', 'DOI': '10.1056/NEJMc2207519', 'volume': '387', 'author': 'E Takashita', 'year': '2022', 'unstructured': 'Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and ' 'antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N ' 'Engl J Med. 2022;387(5):468–70.', 'journal-title': 'N Engl J Med'}, { 'key': '891_CR45', 'unstructured': 'European Medicines Agency. Withdrawal assessment report for Lagevrio. ' 'First published 08 September, 2023. Amsterdam: EMA. 2023. ' 'https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/lagevrio. ' 'Accessed 24 Sept 2023.'}, { 'key': '891_CR46', 'doi-asserted-by': 'publisher', 'author': 'JR Arribas', 'year': '2022', 'unstructured': 'Arribas JR, Bhagani S, Lobo SM, et al. Randomized trial of molnupiravir ' 'or placebo in patients hospitalized with Covid-19. NEJM Evid. 2022. ' 'https://doi.org/10.1056/EVIDoa2100044.', 'journal-title': 'NEJM Evid', 'DOI': '10.1056/EVIDoa2100044'}, { 'key': '891_CR47', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj-2022-072705', 'volume': '380', 'author': 'Y Xie', 'year': '2023', 'unstructured': 'Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or ' 'death in adults with Covid-19: emulation of a randomized target trial ' 'using electronic health records. BMJ. 2023;380: e072705.', 'journal-title': 'BMJ'}, { 'issue': '10359', 'key': '891_CR48', 'doi-asserted-by': 'publisher', 'first-page': '1213', 'DOI': '10.1016/S0140-6736(22)01586-0', 'volume': '400', 'author': 'CHK Wong', 'year': '2022', 'unstructured': 'Wong CHK, Au ICH, Lau KTK, et al. Real-world effectiveness of ' 'molnupiravir and nirmatrelvir plus ritonavir against mortality, ' 'hospitalisation, and in-hospital outcomes among community-dwelling, ' 'ambulatory patients with confirmed SARS-CoV-2 infection during the ' 'Omicron wave in Hong Kong: an observational study. Lancet. ' '2022;400(10359):1213–22.', 'journal-title': 'Lancet'}, { 'key': '891_CR49', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.lanwpc.2022.100602', 'volume': '30', 'author': 'AK Wai', 'year': '2023', 'unstructured': 'Wai AK, Chan CY, Cheung AW, et al. Association of molnupiravir and ' 'nirmatrelvir-ritonavir with preventable mortality, hospital admissions ' 'and related avoidable healthcare system cost among high-risk patients ' 'with mild to moderate COVID-19. Lancet Reg Health West Pac. 2023;30: ' '100602.', 'journal-title': 'Lancet Reg Health West Pac'}, { 'key': '891_CR50', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj-2022-074572', 'volume': '381', 'author': 'Y Xie', 'year': '2023', 'unstructured': 'Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of ' 'Covid-19: cohort study. BMJ. 2023;381:e074572.', 'journal-title': 'BMJ'}, { 'issue': '1', 'key': '891_CR51', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.28186', 'volume': '95', 'author': 'V Mazzotta', 'year': '2023', 'unstructured': 'Mazzotta V, Lepri AC, Colavita F, et al. Viral load decrease in ' 'SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment ' 'with monoclonal antibodies and direct antiviral agents. J Med Virol. ' '2023;95(1):e28186.', 'journal-title': 'J Med Virol'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-023-00891-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-023-00891-1/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-023-00891-1.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 11, 23]], 'date-time': '2023-11-23T07:12:43Z', 'timestamp': 1700723563000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-023-00891-1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11, 23]]}, 'references-count': 51, 'alternative-id': ['891'], 'URL': 'http://dx.doi.org/10.1007/s40121-023-00891-1', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2023, 11, 23]]}, 'assertion': [ { 'value': '11 August 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '31 October 2023', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '23 November 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Julie M. Strizki, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, ' 'Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, and Carisa De Anda are ' 'employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., ' 'Rahway, NJ, USA\xa0(MSD), who may own stock and/or hold stock options in Merck ' '& Co., Inc., Rahway, NJ, USA. Jiejun Du and Jay A. Grobler were employees of ' 'Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA\xa0' '(MSD), at the time the study was conducted. Jiejun Du is currently an employee ' 'of Moderna, and Jay A. Grobler is currently an employee of Pfizer Inc.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest'}}, { 'value': 'Our company’s\xa0approach to the conduct of clinical trials is in accordance ' 'with the ethical principles that have their origin in the Declaration of ' 'Helsinki, and that are consistent with Good Clinical Practice and the ' 'applicable regulatory requirement(s). The trial was conducted in accordance ' 'with principles of Good Clinical Practice and was approved by the appropriate ' 'institutional review boards/ethics committees and regulatory agencies at all ' 'institutions/study sites (see Table\xa0S8). Written informed consent was ' 'provided by all participants prior to their enrollment into the trial. No ' 'identifying information for any trial participant is included in the ' 'manuscript. All named authors meet the International Committee of Medical ' 'Journal Editors (ICMJE) criteria for authorship on this publication, take ' 'responsibility for the integrity of the work as a whole, and have given their ' 'approval for this final version to be published.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethical Approval'}}]}